BioMarin Pharma (BMRN) Tops Q3 EPS, Lowers FY Revenue Guidance

BioMarin Pharma (NASDAQ: BMRN) reported Q3 GAAP EPS of $4.01, which may not compare to the analyst estimate of $1.29. Revenue for the quarter came in at $476.8 million versus the consensus estimate of $454.64 million.

GUIDANCE:

BioMarin Pharma sees FY2020 revenue of $1.81-1.87 billion, versus prior of $1.85-$1.95 billion and the consensus of $1.86 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance